New Alzheimer’s Drugs Create Prescribing Dilemmas for Doctors

Columbia Alzheimer's Specialist Lawrence S. Honig, MD, PhD speaks about the people who have received the new monoclonal antibody Alzheimer’s drugs as a third member of this family of drugs,  donanemab, has become approved. Dr. Honig, like many neurologists, notes that these drugs clearly have clinical efficacy at slowing disease, but that there are uncertainties over the risks versus benefits and important details such as duration of treatment. While uncommon, there have been some deaths due to the side-effects of these drugs, including one person at Columbia who developed the brain swelling known as amyloid-related imaging abnormality (ARIA). [read more]

Source: Science